Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.

ABSTRACT:

Background

To date, no medication has slowed the progression of Parkinson's disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exercising at high intensity, in terms of slowing disease progression, beyond the well-documented benefit of endurance training on a treadmill for fitness, gait, and functional mobility. This study will determine the efficacy of high-intensity endurance exercise as first-line therapy for persons diagnosed with PD within 3 years, and untreated with symptomatic therapy at baseline.

Methods

This is a multicenter, randomized, evaluator-blinded study of endurance exercise training. The exer

SUBMITTER: Patterson CG 

PROVIDER: S-EPMC9535216 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature